{"id":"vi-dt-multi-dose-formulation","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL508727","moleculeType":"Small molecule","molecularWeight":"392.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of Vi-DT is not fully understood, but it is believed to work by inducing a strong immune response against the O:1a serotype of Salmonella Typhi, the bacteria that causes typhoid fever. This immune response is thought to provide long-term protection against typhoid fever.","oneSentence":"Vi-DT is a vaccine that stimulates the immune system to produce antibodies against a specific target.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:46.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever"}]},"trialDetails":[{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein"],"phase":"phase_3","status":"active","brandName":"Vi-DT (Multi-dose formulation)","genericName":"Vi-DT (Multi-dose formulation)","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Vi-DT (Multi-dose formulation) is a small molecule vaccine used to study immune equivalence against Typhoid. It is being compared to a single dose formulation and a control vaccine in a Phase III clinical trial (NCT04204096) to evaluate its safety and immune response.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}